Migraine Prevention Drugs Linked to Lower Glaucoma Risk

Certain Migraine Prevention Drugs Linked to Lower Glaucoma Risk

New research suggests that a specific class of medications used to prevent migraines may also help protect against glaucoma, a leading cause of blindness. A study published May 6, 2026, in the medical journal Neurology found an association between the use of calcitonin gene-related peptide (CGRP) inhibitors and a reduced risk of developing the eye condition.

While the findings are promising, researchers emphasize that the study shows an association rather than a direct cause-and-effect relationship. However, the data provides critical insights into how vascular health in the brain and eyes may be linked.

Understanding the Link Between Migraines and Glaucoma

Glaucoma occurs when damage to the optic nerve—often caused by abnormally high pressure in the eye—leads to vision loss. Interestingly, migraine sufferers may already be at a higher risk for the condition.

According to study author Chien-Hsiang Weng, MD, MPH, of Brown University, both migraines and glaucoma affect how blood vessels in the brain alter blood flow in response to various stimuli. Because CGRP inhibitors help regulate inflammation and blood vessel contraction within the nervous system, researchers hypothesized that these drugs might offer protective benefits for eye health.

Study Design and Key Findings

The research team analyzed a health care database, tracking 36,822 people who were newly prescribed CGRP inhibitors and had at least one refill. They compared this group to an equal number of people taking other types of migraine prevention medications. The participants were followed for up to three years.

The results revealed a notable difference in glaucoma development:

• CGRP Inhibitor Group: 153 people (0.42%) developed glaucoma.
• Non-CGRP Inhibitor Group: 223 people (0.61%) developed glaucoma.

After adjusting for variables such as age, history of high blood pressure, and the frequency of migraines, those taking CGRP inhibitors had a 25% lower risk of developing glaucoma compared to those taking other preventive drugs.

Not All Migraine Drugs are Equal

The study highlighted a crucial distinction between the types of CGRP-targeting medications. The reduced risk of glaucoma was only evident in patients using monoclonal antibodies. These include:

• Erenumab
• Fremanezumab
• Galcanezumab
• Eptinezumab

The benefit was not found in patients taking CGRP receptor antagonists, also known as “gepants,” such as atogepant and rimegepant.

For comparison, the non-CGRP inhibitor group included patients taking medications such as topiramate, valproate, amitriptyline, venlafaxine, flunarizine, candesartan, lisinopril, metoprolol, propranolol, and nadolol.

Limitations and Next Steps

While the 25% risk reduction is significant, the study has limitations. Researchers were unable to account for the participants’ family history of glaucoma or other specific risk factors that could have influenced the outcome.

Dr. Weng noted that further studies are necessary to confirm these results. If verified, these findings could deepen the medical community’s understanding of the shared pathways between migraine and glaucoma, potentially leading to new preventative strategies for patients at risk of blindness.

Frequently Asked Questions

Do CGRP inhibitors cure glaucoma?

No. The study indicates that these drugs are associated with a reduced risk of developing glaucoma; it does not suggest they are a cure or a primary treatment for the condition.

Which migraine drugs were NOT linked to lower glaucoma risk?

CGRP receptor antagonists (gepants), specifically atogepant and rimegepant, did not show the same reduced risk as the monoclonal antibodies.

Why are migraines linked to glaucoma?

Both conditions involve the capacity of blood vessels in the brain to manage blood flow in response to stimuli, suggesting a shared vascular vulnerability.